Clinical trial
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone…
NCT00201864 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00201864 |
|---|---|
| Title | Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer |
| Official title | Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Exemestane, Fulvestrant |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2012 |
| Completion | Feb 1, 2014 |
| First posted | Sep 20, 2005 |
| Last update posted | Jul 26, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: